Human epicardial adipose tissue-derived and circulating secreted frizzled-related protein 4 (SFRP4) levels are increased in patients with coronary artery disease

Qingwei Ji1,2†, Jianwei Zhang3,4†, Yu Du3,4†, Enjun Zhu5, Zhijian Wang3,4, Bin Que1,2, Huangtai Miao1,2, Shutian Shi1,2, Xiuchuan Qin1,2, Yingxin Zhao3,4, Yujie Zhou3,4, Fangjun Huang5 and Shaoping Nie1,2*

Abstract

Background: Previous studies have demonstrated that secreted frizzled-related protein 4 (SFRP4) is associated with impaired glucose and triglyceride metabolism in patients with stable coronary artery disease. In the present study, we investigated human epicardial adipose tissue (EAT)-derived and circulating SFRP4 levels in patients with coronary artery disease (CAD).

Methods: Plasma samples and adipose biopsies from EAT and subcutaneous adipose tissue (SAT) were collected from patients with CAD (n = 40) and without CAD (non-CAD, n = 30) during elective cardiac surgery. The presence of CAD was identified by coronary angiography. SFRP4 mRNA and protein expression levels in adipose tissue were detected by quantitative real-time PCR and immunohistochemistry, respectively. Plasma SFRP4 concentrations were measured by an enzyme-linked immunosorbent assay (ELISA). Correlation analysis and multivariate linear regression analysis were used to determine the association of SFRP4 expression with atherosclerosis as well as clinical risk factors.

Results: SFRP4 mRNA and protein expression levels were significantly lower in EAT than in paired SAT in patients with and without CAD (all \( P < 0.05 \)). Compared to non-CAD patients, CAD patients had higher SFRP4 expression levels in EAT (both mRNA and protein levels) and in plasma. Multivariate linear regression analysis showed that CAD was an independent predictor of SFRP4 expression levels in EAT (\( \beta = 0.442, 95\% \text{ CI} 0.030–0.814; P = 0.036 \)) and in plasma (\( \beta = 0.300, 95\% \text{ CI} 0.056–0.545; P = 0.017 \)). SAT-derived SFRP4 mRNA levels were independently associated with fasting insulin levels (\( \beta = 0.382, 95\% \text{ CI} 0.008–0.756; P = 0.045 \)). In addition, plasma SFRP4 levels were positively correlated with BMI (\( r = 0.259, P = 0.030 \)), fasting insulin levels (\( r = 0.306, P = 0.010 \)) and homeostasis model assessment of insulin resistance (HOMA-IR) values (\( r = 0.331, P = 0.005 \)).

Conclusions: EAT-derived and circulating SFRP4 expression levels were increased in patients with CAD. EAT SFRP4 mRNA levels and plasma SFRP4 concentrations were independently associated with the presence of CAD.

Keywords: Epicardial adipose tissue, SFRP4, Atherosclerosis, Coronary artery disease

*Correspondence: spnie@126.com
†Qingwei Ji, Jianwei Zhang and Yu Du contributed equally to this work
1 Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China
Full list of author information is available at the end of the article

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Accumulating evidence has established that the pathogenesis of obesity-related metabolic disorders involves a chronic, low-grade inflammatory state. Adipose tissue is a persistent active endocrine organ, secreting numerous pro- and anti-inflammatory adipokines in a paracrine or endocrine pathway, and this secretion pattern is altered in certain pathological conditions involving atherosclerosis [1]. Due to the distinctive location and multifaceted metabolic properties of epicardial adipose tissue (EAT), the association of adipokines derived from EAT and atherosclerosis has been widely investigated [2–4]. Furthermore, a series of adipokines has been shown to accelerate or alleviate the initiation and progression of atherosclerosis, which provides a promising therapeutic target for the treatment of obesity-related diseases including atherosclerosis [5, 6].

Wingless and Int-1 (Wnt) signaling is involved in embryonic development, adipogenesis, carcinogenesis and atherosclerosis [7–10]. The secreted frizzled-related protein family consists of 5 members (SFRP 1-5) in humans and antagonizes Wnt signaling [11]. SFRP4 is an adipokine, and serum SFRP4 levels have been shown to be elevated in patients with different types of diabetes, even a few years before clinical diagnosis of diabetes [12, 13]. Moreover, circulating SFRP4 levels are positively correlated with glucose, insulin, glycated hemoglobin and the homeostasis model assessment of insulin resistance (HOMA-IR) values [14]. Serum SFRP4 levels in patients with stable coronary artery disease (CAD) are also positively correlated with body mass index (BMI), waist circumference and triglycerides, all contributors to metabolic syndrome [15]. In addition, SFRP 4 mRNA levels are increased in visceral adipose tissue from obese individuals and are elevated in human failing hearts due to dilated cardiomyopathy or CAD [16, 17].

Although circulating SFRP4 levels have been widely recognized as a novel biomarker of β-cell dysfunction, insulin resistance and other metabolic disorders, little is known about serum and EAT-derived SFRP4 expression in patients with CAD. EAT is not separated from the myocardium or coronary artery vascular wall by fascia [2]; thus, SFRP4 might have a direct effect on atherosclerosis through a paracrine or vasocrine pathway. To clarify this issue, human SFRP4 expression levels in EAT and plasma were measured in patients with and without CAD who underwent elective cardiac surgery.

Methods
Subjects
The study enrolled 70 patients who underwent elective cardiac surgery from January to October 2015. All patients were divided into either a CAD (n = 40) or non-CAD (n = 30) group according to coronary angiography. The CAD group included patients undergoing off-pump coronary artery bypass grafting (CABG) due to left main disease, three-vessel disease or two-vessel disease with a proximal left anterior descending lesion. The non-CAD group included individuals undergoing open-heart surgery for atrial septal defect repair or valvular replacement, with no stenosis found in the coronary artery lumen. The exclusion criteria consisted of age > 75 years, acute myocardial infarction, severe heart failure or cardiogenic shock, active phase of infectious or rheumatic immune disease, liver or renal failure, or pharmacological glucocorticoid or immunosuppressive therapy.

The study complied with the Declaration of Helsinki and was approved by the Ethics Committee of Beijing Anzhen Hospital of Capital Medical University. Written informed consent was obtained from each patient.

Clinical data collection
Demographic data, body weight, height, medical history and medication use were recorded on admission to the hospital. BMI was calculated as weight (kg) divided by the square of height (m²).

Blood sample measurement
Fasting venous blood samples were obtained from all participants on the morning following admission. Blood samples were collected in sodium heparin vacuum containers (Becton–Dickinson) and centrifuged for 15 min at 3000 × g, and then, plasma samples were stored at −80 °C. The lipid profiles and levels of fasting glucose, insulin, Glycosylated serum protein and high-sensitivity C-reactive protein (hsCRP) were measured in the central laboratory of Beijing Anzhen Hospital. Insulin sensitivity was evaluated by the HOMA-IR, which was calculated as fasting glucose (mmol/L) × fasting insulin (µU/mL)/22.5.

Plasma SFRP4 levels were measured in duplicate by a commercially available enzyme-linked immunosorbent assay (ELISA) kits (Biomatik, Canada) following the manufacturer’s instructions. The ELISA intra-assay and inter-assay coefficients of variation were both < 5%.

Adipose tissue acquisition
Paired samples (average 0.3 g each) of EAT and subcutaneous adipose tissue (SAT) were obtained from the proximal right coronary artery and the site of the chest incision from 16 patients with CAD and 13 non-CAD patients, who were randomized selected from CAD group and non-CAD group, respectively. The adipose tissue samples were rinsed with phosphate-buffered saline, followed by division into two portions. One portion was immersed in neutralized formalin for
Immunohistochemical analysis and the other was frozen in liquid nitrogen for RNA isolation.

**RNA isolation and quantitative real-time PCR**

Total RNA was extracted from adipose tissue samples using the Trizol reagent (Invitrogen, USA). The concentration and purity of isolated RNA were evaluated by calculating the ratio of optical density at 260 nm (OD260) and 280 nm (OD 280), and the integrity of RNA was determined by the 18S and 28S ribosomal bands. RNA (2 µg) was used for reverse transcription using the GoScript Reverse Transcription System (Promega, USA).

Quantitative real-time PCR analysis was performed with a CFX Real-Time PCR Detection System (Bio-Rad, USA). Each reaction included: 1 µL of cDNA, 0.5 µL of each primer (10 µmol/L), 10 µL of SYBR Premix Ex Taq(TM) (TAKARA, Japan) and 8 µL of sterile water. The mRNA amplification conditions were 1 min at 95 °C, followed by 44 cycles of 5 s at 95 °C and 30 s at 60 °C, then 0.5 °C increments every 5 s from 55 to 95 °C. All the PCR efficiencies ranged from 90 to 105%.

The primers were designed using Primer Premier 6.0 software (Premier, Canada) with their sites spanning introns. The sequences were as follows SFRP4, forward 5'-GGACCCCTGCCAAGTTCAAG-3', reverse 5'-ACGGCATACTGTAGTC-3'; β-actin, forward 5'-AGTCTACCATGGATGCAAT-3', reverse 5'-ACTCGTACTCCTGCTTG-3'. Threshold cycle values were recorded and relative gene expression was calculated using the formula $2^{-\Delta \Delta CT}$.

**Immunohistochemistry**

Available EAT and paired SAT samples were randomly selected from the CAD group (n = 8) and the non-CAD group (n = 8). Paraffin-embedded serial biopsy sections were deparaffinized and rehydrated, followed by staining with hematoxylin and eosin. Selected sections were incubated in 3% H2O2 for 15 min, and then blocked with normal goat serum for 20 min, followed by incubation with the primary antibody (SFRP4, 1:50 dilution, Abcam, USA) at 4 °C overnight in a moisture chamber after removal of excess serum. The slides were incubated with biotinylated secondary antibodies for 20 min, avidin–biotin reagents for 20 min, followed by diaminobenzidine (DAB) and counterstained for 1 min with hematoxylin. High quality images were observed with a light microscope and recorded. Positive staining for SFRP4 was indicated by a brown color. Expression of SFRP4 was quantified by calculating the integrated optical density (IOD) of positively stained tissue using Image-Pro plus software 6.0 (Media Cybernetics, USA). The IOD of each section was calculated from four separate fields viewed at 100 × magnification.

**Statistical analysis**

Continuous data are expressed as the mean ± SD or the median (lower quartile, upper quartile), as appropriate. Mean values were compared using Student’s t test, and median values were compared using the Mann–Whitney U test. Categorical variables are expressed as percentages and were analyzed by a Chi square test. The Spearman or Pearson correlation tests were performed to compare SFRP4 levels and clinical variables. The associations between SFRP4 levels and clinical factors, including CAD (present (1)/not present (0)), were determined by univariate analysis and multivariate linear regression analysis. All statistical analyses were performed using SPSS 22.0 software (SPSS, Inc., Chicago, IL, USA). A value of $P < 0.05$ was considered statistically significant.

**Results**

**Patient characteristics**

The baseline characteristics of the patients are shown in Table 1. Plasma SFRP4 concentrations were significantly higher in patients with CAD than in those without CAD (16.8 ± 3.3 ng/mL vs 14.5 ± 2.3 ng/mL, $P < 0.001$). Compared to non-CAD patients, CAD patients were more likely to have lower total cholesterol and low-density lipoprotein cholesterol levels, partially due to increased patients use of prescription statins in the CAD group. In addition, aspirin and nitrates were also more frequently used by CAD patients. This medication use pattern was also observed in patients with or without CAD who provided adipose tissue. No significant differences in age, sex, BMI, diabetes, hypertension, use of other current medications or of other laboratory examinations were observed.

**Quantitative real-time PCR analysis**

As shown in Fig. 1a, SFRP4 mRNA levels were significantly lower in EAT than in paired SAT samples in both the CAD group (0.23 vs 0.61, $P = 0.017$) and the non-CAD group (0.19 vs 0.93, $P = 0.002$). Figure 1b shows that EAT SFRP4 mRNA levels were markedly increased in CAD patients compared to non-CAD patients (1.60 vs 0.92, $P = 0.017$), while SAT SFRP4 mRNA levels were not markedly different between the two groups (1.38 vs 0.93, $P = 0.069$).

**Immunohistochemical analysis**

Figure 2A shows representative immuno-stained adipose sections from patients in the CAD group (Fig. 2A-a, b) and the non-CAD group (Fig. 2A-c, d), and reveals that SFRP4 protein was expressed in both EAT and SAT, most prominently in the cytoplasm, as well as in the stromal vasculature. As shown in Fig. 2B, SFRP4 protein levels were higher in SAT than in the
Table 1 Baseline characteristics of patients in the CAD vs non-CAD groups

|                          | Total—CAD (40) | Total—non-CAD (30) | Adipose—CAD* (16) | Adipose—non-CAD* (13) |
|--------------------------|---------------|--------------------|-------------------|----------------------|
| Age (years)              | 60.9 ± 6.6    | 58.2 ± 6.3         | 59.6 ± 9.0        | 57.8 ± 6.4           |
| Male (%)                 | 31 (77.5)     | 17 (56.7)          | 11 (68.8)         | 7 (53.8)             |
| BMI (kg/m²)              | 25.9 ± 2.9    | 24.7 ± 3.0         | 26.2 ± 2.0        | 24.5 ± 2.6           |
| LVEF (%)                 | 58.1 ± 9.3    | 56.2 ± 9.5         | 62.0 ± 7.9        | 60.5 ± 5.7           |
| Fasting glucose (mmol/L) | 6.2 (5.7, 7.8) | 5.4 (5.0, 6.5)    | 6.6 (5.6, 7.5)    | 6.2 (5.1, 8.1)       |
| Glycosylated serum protein (%) | 15.2 (13.8, 18.3) | 15.1 (13.8, 18.5) | 17.4 (13.4, 19.4) | 14.7 (13.6, 15.7)    |
| Fasting insulin (uU/mL)  | 36.1 (24.4, 53.3) | 24.1 (13.4, 36.2) | 35.2 (18.8, 74.4) | 21.7 (14.0, 32.1)    |
| HOMA-IR                  | 9.8 (6.7, 15.2) | 6.1 (3.4, 10.0)   | 9.0 (6.4, 26.2)   | 5.1 (3.6, 9.6)       |
| Triglycerides (mmol/L)   | 1.5 (1.0, 2.4) | 1.5 (1.0, 1.9)    | 1.9 (1.1, 2.5)    | 1.2 (0.7, 1.7)       |
| Total cholesterol (mmol/L) | 4.0 ± 1.1    | 4.7 ± 0.9*         | 4.1 ± 1.1         | 4.6 ± 0.8            |
| HDL-C (mmol/L)           | 1.0 (0.8, 1.3) | 1.2 (0.9, 1.5)    | 1.0 (0.8, 1.2)    | 1.2 (0.8, 1.4)       |
| LDL-C (mmol/L)           | 2.6 ± 0.9     | 3.2 ± 0.9*         | 2.4 ± 0.9         | 2.8 ± 0.8            |
| hsCRP (mg/L)             | 1.8 (0.9, 3.1) | 1.3 (0.5, 4.0)    | 2.2 (1.0, 3.0)    | 1.2 (0.5, 3.0)       |
| SFRP4 (ng/mL)            | 16.8 ± 3.3    | 14.5 ± 2.3**       | 15.7 ± 3.2        | 13.3 ± 2.4*          |
| Hypertension (%)         | 19 (47.5)     | 9 (30.0)           | 6 (37.5)          | 5 (38.5)             |
| T2DM (%)                 | 14 (35.0)     | 6 (20.0)           | 7 (43.8)          | 2 (15.4)             |
| Smoking (%)              | 16 (40.0)     | 7 (23.3)           | 6 (37.5)          | 2 (15.4)             |
| Aspirin (%)              | 34 (85.0)     | 4 (13.3)**         | 13 (81.3)         | 3 (23.1)*             |
| Nitrates (%)             | 38 (95.0)     | 5 (16.7)**         | 15 (93.8)         | 3 (23.1)*             |
| ACEI/ARB (%)             | 14 (35.0)     | 5 (16.7)           | 4 (25.0)          | 2 (15.4)             |
| Statins (%)              | 23 (57.5)     | 5 (16.7)**         | 7 (43.8)          | 1 (7.7)*              |
| β-Blockers (%)           | 17 (42.5)     | 6 (20.0)           | 8 (50.0)          | 3 (23.1)             |
| Calcium channel blockers (%) | 10 (25.0)   | 2 (6.7)            | 4 (25.0)          | 1 (7.7)              |
| Hypoglycemic agents (%)  | 13 (32.5)     | 5 (16.7)           | 7 (43.8)          | 2 (15.4)             |

Data are shown as mean ± SD, median (lower quartile, upper quartile), or number (%)

CAD coronary artery disease, BMI body mass index, LVEF left ventricular ejection fraction, HOMA-IR homeostasis model assessment of insulin resistance, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, hsCRP high-sensitivity C-reactive protein, T2DM type 2 diabetes, ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin II type 1 receptor blocker

* P < 0.05, Total—CAD vs Total—non-CAD
** P < 0.01, Total—CAD vs Total—non-CAD
* P < 0.05, Adipose—CAD vs Adipose—non-CAD
† P < 0.01, Adipose—CAD vs Adipose—non-CAD

Fig. 1 Quantitative real-time PCR analysis for SFRP4 in human adipose tissue. a Relative SFRP4 mRNA levels in paired adipose tissue in CAD group (n = 16) and non-CAD group (n = 13). b EAT or SAT derived SFRP4 relative mRNA levels in CAD group (n = 16) and non-CAD group (n = 13).

* P < 0.05; ** P < 0.01. CAD coronary artery disease, EAT epicardial adipose tissue, SAT subcutaneous adipose tissue, NS not significant
paired EAT in both the CAD group (13,874.5 vs 9214.5, \(P = 0.039\)) and the non-CAD group (9883 vs 5844, \(P = 0.016\)). Furthermore, SFRP4 protein levels in EAT were significantly higher in CAD patients than in non-CAD patients (9214.5 vs 5844, \(P = 0.021\)), while SFRP4 protein expression in SAT was not different between patients with or without CAD (13,874.5 vs 9883, \(P = 0.105\)).

**Association of SFRP4 levels with coronary atherosclerosis**

Table 2 shows that in the univariate analysis, EAT-derived SFRP4 mRNA levels were positively associated with CAD (beta = 0.430, 95% CI 0.074–0.787). Moreover, this association was found to be independent of age, BMI and fasting glucose in a multivariate linear regression model (beta = 0.442, 95% CI 0.030–0.814; \(P = 0.036\)). In contrast, as seen in Table 3, SAT-derived SFRP4 mRNA levels were not associated with CAD (\(P = 0.086\)) but were found to be positively associated with fasting insulin in a multivariate linear regression model adjusted for age, BMI and CAD (beta = 0.382, 95% CI 0.008–0.756; \(P = 0.045\)). In addition, SAT-derived SFRP4 mRNA levels were positively correlated with HOMA-IR values (\(r = 0.386, P = 0.038\)).

Plasma SFRP4 levels were positively correlated with the BMI (\(r = 0.259, P = 0.030\)), fasting insulin levels (\(r = 0.306, P = 0.010\)) and HOMA-IR values (\(r = 0.331, P = 0.005\)). As shown in Table 4, multivariate linear regression analysis indicated that plasma SFRP4 levels were independently associated with the presence of CAD (beta = 0.300, 95% CI 0.056–0.545; \(P = 0.017\)) after adjusting for age, BMI, HOMA-IR and triglycerides.

**Table 2 Association between EAT SFRP4 mRNA levels and variables using univariate analysis and multivariate linear regression analysis**

| Variables  | Univariate | Multivariate |
|------------|------------|--------------|
|            | Beta       | 95% CI       | \(P\) value | Beta       | 95% CI       | \(P\) value |
| Age        | -0.028     | -0.423 to 0.366 | 0.884      | -0.053     | -0.422 to 0.316 | 0.770      |
| BMI        | 0.187      | -0.201 to 0.575 | 0.331      | 0.158      | -0.270 to 0.585 | 0.454      |
| Fasting glucose | -0.145 | -0.536 to 0.246 | 0.453      | -0.272     | -0.679 to 0.134 | 0.180      |
| CAD        | 0.430      | 0.074 to 0.787 | 0.020      | 0.442      | 0.030 to 0.814 | 0.036      |

EAT: epicardial adipose tissue, CI: confidence interval, BMI: body mass index, CAD: coronary artery disease (presence: 1/not presence: 0)
Many studies have indicated that adipokines, such as adiponectin, leptin, chemerin and omentin, serve as biomarkers of CAD [3–6]. The association of adiponectin with CAD has been widely investigated in previous studies [4, 18–23]. We demonstrated that both circulating and EAT adiponectin levels are decreased in CAD patients [4, 18]. Additionally, we found that adiponectin deficiency in perivascular adipose tissue promoted atherosclerosis [19]. Moreover, Wang et al. reported that over-expression of adiponectin significantly inhibited the formation of atherosclerotic plaques in ApoE−/− mice [20], suggesting a protective role of adiponectin in atherosclerotic disease. Furthermore, accumulating clinical evidence has demonstrated that circulating adiponectin levels are not only associated with the onset of CAD but are also independently associated with cardiovascular mortality [18, 20–23]. Recently, we found that the levels of circulating and EAT omentin-1 were decreased in CAD patients compared to non-CAD patients. However, the expression of SAT SFRP4 was not different in these groups. Interestingly, plasma SFRP4 levels were positively correlated with BMI, fasting insulin levels and HOMA-IR values, which were not revealed in EAT SFRP4. Additionally, CAD was an independent predictor of the increased EAT and plasma SFRP4 levels. The results suggest that SFRP4 is a novel biomarker of CAD and might play a role in the development of CAD.

SFRP4 is a member of the SFRP family that was identified as a heparin-binding polypeptide in conditioned medium from a human embryonic lung fibroblast line in 1997 [24]. Immature SFRP4 is a 36 kDa protein that contains a signal peptide, an N-terminal cysteine-rich domain that is 30–40% identical to a putative Wnt-binding domain of Frizzled, and a hydrophilic carboxyl terminus. Additionally, the circulating form of mature sFRP4 is a 48 kDa protein after posttranslational glycosylation. The SFRP4 gene is also found in monkeys, mice, pigs and toads, but is not detected in fruit flies or yeast. SFRP4 expression displays temporal and spatial characteristics during embryonic development. Additionally, SFRP4 is expressed in a tissue-specific manner in adult humans, with the highest expression in the heart, followed by the kidneys, ovaries, prostate, testis, small intestine and colon, while the placenta, brain tissue and pancreas

**Table 3  Association between SAT SFRP4 mRNA levels and variables using univariate analysis and multivariate linear regression analysis**

| Variables         | Univariate | Multivariate |
|-------------------|------------|--------------|
|                   | Beta       | 95% CI       | P value | Beta       | 95% CI       | P value |
| Age               | −0.180     | −0.569 to 0.208 | 0.350 | −0.234     | −0.587 to 0.120 | 0.185 |
| BMI               | 0.251      | −0.131 to 0.633 | 0.189 | 0.084      | −0.300 to 0.468 | 0.656 |
| Fasting insulin   | 0.452      | 0.100 to 0.804  | 0.014 | 0.382      | 0.008 to 0.756  | 0.045 |
| CAD               | 0.325      | −0.049 to 0.698 | 0.086 | 0.214      | −0.171 to 0.600 | 0.263 |

SAT subcutaneous adipose tissue, CI confidence interval, BMI body mass index, CAD coronary artery disease (presence (1)/not presence (0))

**Table 4  Association between serum SFRP4 levels and variables using univariate analysis and multivariate linear regression analysis**

| Variables       | Univariate | Multivariate |
|-----------------|------------|--------------|
|                 | Beta       | 95% CI       | P value | Beta       | 95% CI       | P value |
| Age             | 0.158      | −0.081 to 0.397 | 0.191 | 0.076      | −0.154 to 0.306 | 0.513 |
| BMI             | 0.224      | −0.012 to 0.460 | 0.062 | 0.094      | −0.151 to 0.340 | 0.446 |
| HOMA-IR         | 0.275      | 0.043 to 0.508  | 0.021 | 0.171      | −0.075 to 0.417 | 0.170 |
| Triglycerides   | −0.116     | −0.356 to 0.125 | 0.341 | −0.017     | −0.251 to 0.217 | 0.884 |
| CAD             | 0.373      | 0.149 to 0.598  | 0.001 | 0.300      | 0.056 to 0.545  | 0.017 |

CI confidence interval, BMI body mass index, HOMA-IR homeostasis model assessment of insulin resistance, CAD coronary artery disease (presence (1)/not presence (0))

**Discussion**

Many studies have indicated that adipokines, such as adiponectin, leptin, chemerin and omentin, serve as biomarkers of CAD [3–6]. The association of adiponectin with CAD has been widely investigated in previous studies [4, 18–23]. We demonstrated that both circulating and EAT adiponectin levels are decreased in CAD patients [4, 18]. Additionally, we found that adiponectin deficiency in perivascular adipose tissue promoted atherosclerosis [19]. Moreover, Wang et al. reported that over-expression of adiponectin significantly inhibited the formation of atherosclerotic plaques in ApoE−/− mice [20], suggesting a protective role of adiponectin in atherosclerotic disease. Furthermore, accumulating clinical evidence has demonstrated that circulating adiponectin levels are not only associated with the onset of CAD but are also independently associated with cardiovascular mortality [18, 20–23]. Recently, we found that the levels of circulating and EAT omentin-1 were decreased in CAD patients compared to non-CAD patients [4]. Furthermore, CAD is an independent predictor of EAT and circulating omentin-1 levels. Taken together, these findings support a close association of EAT-derived adipokines with the onset of CAD.

In the present study, we found that EAT and circulating SFRP4 levels were increased in CAD patients compared
SFRP4 binds directly to Wnt, modulates both canonical and non-canonical Wnt pathways and is therefore involved in the embryonic developmental pathway and adult pathological processes. For example, many studies have identified a close association of SFRP4 with tumors [25–30]. SFRP4 mRNA is over-expressed in primary serous ovarian tumors but decreased in prostate cancers, endometrial stromal sarcomas, lung squamous cell carcinoma and pancreatic tumors [25–29]. Low SFRP4 expression is associated with an unfavorable prognosis in prostate and ovarian cancer [26, 30]. Additionally, some studies have shown that SFRP4 participates in apoptosis [31, 32], angiogenesis [33, 34], and bone formation [35, 36]. Notably, Matsushima et al. reported that the expression of SFRP4 in the heart was increased in a rat infarction model, while treatment with recombinant SFRP4 reduced fibrosis scar size and improved impaired heart function [37], suggesting a protective role of SFRP4 in myocardial infarction, which is a severe form of CAD.

Recently, accumulating evidence has identified SFRP4 as a novel adipokine [11–17]. Ehrlund et al. found that SFRP4 is secreted from human white adipose tissue (WAT), and SFRP4 expression is up-regulated both in human SAT and visceral WAT in obese compared to lean subjects [17]. These results are consistent with the findings of Garufi [38], who reported that circulating and abdominal SAT SFRP4 levels were significantly increased in obese individuals and abdominal SAT is the main source of circulating SFRP4 in obese subjects. In the present study, we found that EAT SFRP4 expression significantly increased in CAD patients compared to non-CAD patients, although EAT SFRP4 expression was lower than SAT SFRP4 expression both in patients with and without CAD, suggesting that the increase in circulating SFRP4 can be partially accounted for by the high expression of EAT SFRP4 in CAD patients. SFRP4 plays a critical role in the control of adipogenesis. Park et al. found that SFRP4 mRNA was up-regulated gradually during adipogenic differentiation in human adipose tissue-derived mesenchymal stem cells (hAMSCs) [11]. Moreover, blocking SFRP4 inhibition with small interfering RNA inhibited differentiation of hAMSCs into adipocytes and restored β-catenin levels, suggesting that SFRP4 promotes adipocyte differentiation via suppressing the canonical Wnt pathway [11]. Additionally, many studies have demonstrated that SFRP4 is involved in glucose and lipid metabolism and insulin secretion [12, 32]. By analyzing global gene expression in human pancreatic islets, Mahdi et al. found that, accompanied by the expression of inflammatory markers, SFRP4 was up-regulated in patients with type 2 diabetes [12]. SFRP4 treatment resulted in a decrease in insulin secretion and glucose intolerance, while silencing of SFRP4 led to glucose-stimulated insulin release [12]. Furthermore, they found that not only type 2 diabetes patients but also patients who later developed type 2 diabetes had higher serum SFRP4 levels than the controls, although the sample size was small. These clinical results were also demonstrated by later studies [13, 14], which found that SFRP4 levels were significantly increased in impaired glucose tolerance patients and patients with different types of diabetes including type 1 diabetes, type 2 diabetes and latent autoimmune diabetes of the adult (LADA). However, using a diet-induced obesity model, Mastaitis et al. found that SFRP4 deficient mice have normal glucose and insulin levels [39]. These disparate results may be associated with the use of different models. In the present study, we found that SAT SFRP4 mRNA levels were positively correlated with fasting insulin, and circulating SFRP4 levels were positively correlated with HOMA-IR, although no significant correlation between EAT SFRP4 and fasting insulin was observed. These results may be owed to small samples of the present study. Therefore, the effect of SFRP4 on insulin-related metabolism should be further investigated.

Numerous studies have demonstrated that Wnt pathway-related proteins are highly expressed in atherosclerotic lesions, participate in cholesterol transportation, modulate the inflammatory process and thereby play a pivotal role in atherosclerosis [5, 6, 10]. These findings also indicated that SFRP4 may participate in atherosclerosis through regulation of the Wnt pathway. Recently, circulating SFRP4 levels were detected in 504 patients with stable CAD [15]. The results showed that patients with metabolic syndrome, insulin therapy, diabetes and a history of myocardial infarction or percutaneous intervention had higher SFRP4 levels. Correlation analyses have revealed that elevated SFRP4 levels are positively correlated with HbA1c, fasting insulin, BMI and fasting and postprandial triglyceride levels, and these results were also found in our study. After 48 months of follow-up, the baseline SFRP4 level was not associated with the onset of the primary cardiovascular endpoint, although patients experiencing a stroke/transitory ischemic attack had increased SFRP4 levels. This was the first study focusing on SFRP4 in CAD patients. However, since patients without CAD were not enrolled as controls in that study, it is difficult to conclude that the changes in circulating SFRP4 levels were associated with CAD. Therefore, SFRP4 levels of CAD patients and controls were measured in the present study to determine whether SFRP4 levels increase and are associated with the presence of CAD. Although the controls were
not healthy subjects and the sample size was small, the results showed that EAT SFRP4 expression was significantly increased in CAD patients, and CAD is an independent predictor of SFRP4 elevation, indicating that SFRP4 elevation is attributed to the onset of CAD, and participates in the development of CAD via modulation of the Wnt pathway. Furthermore, similar results were obtained regarding plasma SFRP4 levels in both groups.

There are some limitations to our study. First, the sample size is small and should be expanded in the future. Second, circulating SFRP4 levels should be measured in a future study in which patients with different clinical types of CAD, including stable angina, unstable angina and myocardial infarction, as well as healthy controls, are enrolled. Only in this way can the changes in SFRP4 in CAD be clearly distinguished.

In conclusion, our study found for the first time that EAT and plasma SFRP4 levels were increased in patients with CAD. Additionally, both EAT and plasma SFRP4 levels were independently associated with the presence of CAD. Therefore, these results indicated that the novel adipokine SFRP4 is involved in CAD. However, the exact role of SFRP4 in CAD and atherosclerosis remains unknown and should be investigated in prospective studies.

Abbreviations
SFRP4: secreted frizzled-related protein 4; EAT: epicardial adipose tissue; SAT: subcutaneous adipose tissue; CAD: coronary artery disease; PCR: polymerase chain reaction; ELISA: enzyme-linked immunosorbent assay; Wnt: Wingless and Int-1; HOMA-IR: homeostasis model assessment of insulin resistance; BMI: body mass index; CAGB: coronary artery bypass grafting; hsCRP: high-sensitivity C-reactive protein; CT: threshold cycle; DAB: diaminobenzidine; IOD: integrated optical density; HDL-C: high-density lipoprotein cholesterol; CI: confidence interval.

Authors’ contributions
QWJ, JWJ and YD participated in study design and drafted the manuscript. YD, HTM and STS carried out the molecular genetic studies and plasma assessment, performed data collection and reduction, as well as statistical analysis. ZJW and BQ carried out the immunoassays. EJZ, XQZ and FJH collected adipose tissue and serum samples. YXZ and YJZ participated in study design and revised the manuscript critically for important intellectual content. SPN conceived of the study and involved in study design and coordination. All authors read and approved the final manuscript.

Author details
1 Emergency & Critical Care Center, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. 2 Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing 100029, China. 3 Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. 4 Beijing Institute of Heart, Lung, and Blood Vessel Diseases, The Key Laboratory of Remodeling-related Cardiovascular Disease, Ministry of Education, Beijing 100029, China. 5 Department of Cardiac Surgery Center, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.

Acknowledgements
This work was supported by the National Natural Science Foundation of China (Nos. 81560085 and 81670391), National High Technology Research and Development Program of China (863 Program, No. 2015AA020102), International S&T Cooperation Program of China (No. 2015DFAF30160), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201710) and Beijing Lab for Cardiovascular Precision Medicine, Beijing, China (PX2017_014226_000037).

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Consent for publication
This manuscript does not contain any data from any individual person. If the manuscript is accepted, we approve it for publication in Cardiovascular Diabetology.

Ethics approval and consent to participate
The study complied with the Declaration of Helsinki and was approved by the Ethics Committee of Beijing Anzhen Hospital of Capital Medical University. Written informed consent was obtained from each patient.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 13 August 2017 Accepted: 4 October 2017

Published online: 16 October 2017

References
1. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.
2. Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol. 2015;11:363–71.
3. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, Sarov-Blat L, O’Brien S, Keiper EA, Johnson AG, Martin J, Goldstein BJ, Shi Y. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003;108:2460–6.
4. Du Y, J Q, Cai L, Huang F, Lai Y, Liu Y, Yu J, Han B, Zhu E, Zhang J, Zhou Y, Wang Z, Zhao Y. Association between omentin-1 expression in human epicardial adipose tissue and coronary atherosclerosis. Cardiovasc Diabetol. 2016;15:90.
5. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014;63:250–9.
6. Ohashi K, Shibata R, Musahara T, Ouchi N. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab. 2014;25:348–55.
7. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol. 2009;129:1614–27.
8. Christodoulides C, Lagathu C, Sethi JK, Vidal-Puig A. Adipogenesis and WNT signalling. Trends Endocrinol Metab. 2009;20:16–24.
9. Zhan T, Rindtorff N, Boutos M. Wnt signaling in cancer. Oncogene. 2017;36:1461–73.
10. Blankstein WM, Hermans KC. Wnt signaling in atherosclerosis. Eur J Pharmacol. 2015;763:122–30.
11. Park JR, Jung JW, Lee YS, Kang KS. The roles of Wnt antagonists Dkk1 and SFRP4 during adipogenesis of human adipose tissue-derived mesenchymal stem cells. Cell Prolif. 2008;41:859–74.
12. Mahdi T, Hanzellmann S, Salehe A, Muhammed SJ, Reinothe TM, Tang Y, Axelsson AS, Zhou Y, Jing X, Almgren P, Kruis U, Taneera J, Blom AM, Lyssenko V, Esquerra JL, Hansson O, Eliasson L, Derry J, Zhang E, Wollheim CB, Gropo L, Renstrom E, Rosengren AH. Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab. 2012;16:625–33.
13. Reinothe TM, Kraszek EC, Hoebaus C, Ludvik B, Schernthaner G, Schernthaner GH. Secreted frizzled-related protein 4 (SFRP4) is elevated in patients with diabetes mellitus. Horm Metab Res. 2016;48:345–8.
14. Anand K, Vidyasagar S, Lasrado I, Pandey GK, Amutha A, Ranjani H, Anjana RM, Mohan V, Gokulakrishnan K. Secreted frizzled-related protein 4 (SFRP4): a novel biomarker of beta-cell dysfunction and insulin resistance.
in individuals with prediabetes and type 2 diabetes. Diabetes Care. 2016;39:e147–8.

15. Hoffmann MM, Werner C, Bohm M, Laufs U, Winkler K. Association of secreted frizzled-related protein 4 (SFRP4) with type 2 diabetes in patients with stable coronary artery disease. Cardiovasc Diabetol. 2014;13:155.

16. Schumann H, Holtz J, Zerkowski HR, Hatzfledt M. Expression of secreted frizzled-related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression. Cardiovasc Res. 2000;45:720–8.

17. Ehrlund A, Meighert N, Lorente-Cebrian S, Astrom G, Dahlman I, Laurencik-Iene J, Ryden M. Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue. J Clin Endocrinol Metab. 2013;98:E503–8.

18. Ji Q, Lin Y, Liang Z, Yu K, Liu Y, Fang Z, Liu L, Shi Y, Zeng Q, Chang C, Chai M, Zhou Y. Chemerin is a novel biomarker of acute coronary syndrome but not of stable angina pectoris. Cardiovasc Diabetol. 2014;13:145.

19. Liu C, Wang Z, Wang C, Ma Q, Zhao Y. Perivascular adipose tissue-derived adiponectin inhibits collar-induced carotid atherosclerosis by promoting macrophage autophagy. PLoS ONE. 2015;10:e0124031.

20. Wang X, Chen Q, Pu H, Wei Q, Duan M, Zhang C, Jiang T, Shou X, Zhang J, Yang Y. Adiponectin improves NF-κB-mediated inflammation and abates atherosclerosis progression in apolipoprotein E-deficient mice. Lipids Health Dis. 2016;15:33.

21. Moreno LO, Copetti M, Fontana A, De Bonis C, Salvemini L, Trischitta V, Menzaghi C. Evidence of a causal relationship between high serum adiponectin levels and increased cardiovascular mortality rate in patients with type 2 diabetes. Cardiovasc Diabetol. 2016;15:17.

22. Liu G, Ding M, Chiuve SE, Rimm EB, Frank P, Macek JB, Hu FB, Sun Q. Plasma levels of fatty acid-binding protein 4, retinol-binding protein 4, high-molecular-weight adiponectin, and cardiovascular mortality in men with type 2 diabetes: a 22-year prospective study. Arterioscler Thromb Vasc Biol. 2016;36:2259–67.

23. Bergmark BA, Cannon CP, White WB, Jarolim P, Liu Y, Bonaca MP, Zannad F, Morrow DA. Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab. 2017;19:962–9.

24. Finch PW, He X, Kelley MJ, Uren A, Schaudies RP, Popescu NC, Rudikoff S, Aaronson SA, Varmus HE, Rubin JS. Purification and molecular cloning of a secreted, frizzled-related antagonist of Wnt action. Proc Natl Acad Sci USA. 1997;94:6770–5.

25. Drake J, Shearwood AM, White J, Friis R, Zeps N, Charles A, Dharmarajan A. Expression of secreted frizzled-related protein 4 (SFRP4) in primary serous ovarian tumours. Eur J Gynaecol Oncol. 2009;30:133–41.

26. Horvath LG, Henshall SM, Kench JG, Saunders DN, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Koener R, Stricker PD, Grygiel JJ, Sutherland RL. Membranous expression of secreted frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. Clin Cancer Res. 2004;10:615–25.

27. Hrenjak A, Tippl M, Kremsler ML, Strohmeier B, Guelly C, Neumeister D, Lax S, Moinfar F, Tabrizi AD, Isadi-Moud N, Zatiloukal K, Denk H. Inverse correlation of secreted frizzled-related protein 4 and beta-catenin expression in endometrial stromal sarcomas. J Pathol. 2004;204:19–27.

28. Lee EH, Chari R, Lam A, Ng RT, Yee J, English J, Evans KG, Macaulay C, Lam S, Lam WL. Disruption of the non-canonical WNT pathway in lung squamous cell carcinoma. Clin Med Oncol. 2008;2008:169–79.

29. Froeling FE, Feng C, Chelada C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-B-catenin signaling to slow tumor progression. Gastroenterology. 2011;141:1486–97.

30. Jacob F, Ukegjini K, Nkodof S, Ford CE, Oliver J, Caduff R, Scruy JP, Guertler R, Horung D, Mueller R, Funk DA, Hacker NF, Heinzelmann-Schwarz VA. Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients. PLoS ONE. 2012;7:e31885.

31. Maganga R, Giles N, Adcroft K, Unni A, Keeney D, Wood F, Fear M, Dharmarajan A. Secreted frizzled related protein-4 (sFRP4) promotes epidermal differentiation and apoptosis. Biochem Biophys Res Commun. 2008;377:606–11.

32. Viswanwaran M, Schiefer L, Arfuso F, Dilley RJ, Newsholme P, Dharmarajan A. Wnt antagonist secreted frizzled-related protein 4 upregulates adipogenic differentiation in human adipose tissue-derived mesenchymal stem cells. PLoS ONE. 2015;10:e0118805.

33. Muley A, Majumder S, Kolluru GK, Parkinson S, Viola H, Hool L, Arfuso F, Ganss R, Dharmarajan A, Chatterjee S. Secreted frizzled-related protein 4: an angiogenesis inhibitor. Am J Pathol. 2010;176:1505–16.

34. Longman D, Arfuso F, Viola HM, Hool LC, Dharmarajan AM. The role of the cysteine-rich domain and netrin-like domain of secreted frizzled-related protein 4 in angiogenesis inhibition in vitro. Oncol Res. 2012;20:1–6.

35. Nakamichi H, Akiyama H, Kimura H, Otsuki B, Mizuno M, Tsuiboaya T, Nakamura T. Osteoblast-targeted expression of SFRP4 in mice results in low bone mass. J Bone Miner Res. 2008;23:271–7.

36. Nakamichi H, Shimagi M, Mori Y, Akiyama H, Okudaira S, Otsuki B, Hashimoto M, Higuchi X, Hosokawa M, Tsuiboaya T, Nakamura T. Secreted frizzled-related protein 4 is a negative regulator of peak BMD in SAMP6 mice. Endocrinology. 2000;141:2171–21.

37. Matsuhashi K, Suyama T, Takenaka C, Nishihata S, Ikeda K, Ikeda Y, Saya Y, Jakt LM, Mori H, Kawamura S. Secreted frizzled related protein 4 reduces fibrosis scar size and ameliorates cardiac function after ischemic injury. Tissue Eng Part A. 2010;16:3329–41.

38. Garufi G, Seyhan AA, Pasarica M. Elevated secreted frizzled-related protein 4 in obesity: a potential role in adipose tissue dysfunction. Obesity. 2015;23:24–7.

39. Garufi G, Seyhan AA, Pasarica M. Elevated secreted frizzled-related protein 4 in obesity: a potential role in adipose tissue dysfunction. Obesity. 2015;23:24–7.

40. Matsaitis J, Eckdersdorf M, Min S, Xin Y, Cavino K, Agline J, Okamoto H, Na E, Stitt T, Dominguez MG, Schmahl JP, Lin C, Gale NW, Valenzuela DM, Murphy AJ, Yancopoulos GD, Gromada J. Loss of SFRP4 alters body size, food intake, and energy expenditure in diet-induced obese male mice. Endocrinology. 2015;156:4502–10.